Compare Amphastar Pharmaceuticals Inc (AMPH) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs PepsiCo, Inc. — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.3 (market cap $826.08M), while PepsiCo, Inc. trades at $139.93 (market cap $187.51B). The key difference: PepsiCo, Inc. is far larger — about 227× Amphastar Pharmaceuticals Inc's market cap, and PepsiCo, Inc. pays a 4.31% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | PEP | |
|---|---|---|
Market Cap | $826.08M | $187.51B |
Sector | Health | Consumer Staples |
52-Week High | $30.81 | $170.44 |
52-Week Low | $16.87 | $133.81 |
Enterprise Value | $1.22B | $230.01B |
Dividend Yield | — | 4.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
PepsiCo (PEP) trades at $137.99, up 0.44% on the day, with a bearish technical signal but strong fundamentals including a 10.78% net income margin and consistent earnings beats. Recent news highlights price cuts on snacks like Doritos to address consumer resistance, while Q1 2026 results are anticipated. The stock shows robust cash flow from operations of $12.09B in 2025 and a high ROE of 51.59%, though debt-to-asset ratios have risen to 45.85%.
Outlook is mixed: analyst consensus targets $159.27 with 33% buy ratings, but technicals suggest near-term pressure. Risks include competitive pricing pressures and execution of North America turnaround. The dividend yield near 4% and earnings growth potential offer value, yet investors should monitor Q1 results for sustainability signs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
